10-K/A: Cocrystal Pharma Files Amended Annual Report on Form 10-K/A

Cocrystal Pharma has filed an amendment to its annual report to include information required in Part III, which was not included in the original filing.

Summary

• Cocrystal Pharma filed an amendment to its annual report on Form 10-K, specifically to include information required in Part III, which was not included in the original filing due to the company not intending to file its definitive proxy statement within 120 days of the fiscal year end.
• The amendment includes details about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
• The company's board of directors consists of eight members, including two co-chief executive officers, Sam Lee and James Martin.
• The company has an audit committee, a compensation committee, and a corporate governance and nominating committee, each with specific responsibilities.
• The company's executive officers received base salaries of $394,821 and bonuses of $165,000 in 2023.
• The company's largest shareholders include Phillip Frost with 13.10% and Fred Hassan with 9.98% of the outstanding shares.
• The company's audit fees for 2023 were $130,000.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, with no significant positive or negative news. The sentiment is neutral to slightly positive due to the company's adherence to regulatory requirements and established corporate governance.

Positives

• The company has a well-defined corporate governance structure with independent directors.
• The company has established committees for audit, compensation, and corporate governance.
• The company has a code of ethics and an insider trading policy in place.
• The company has a clawback policy to recoup excess incentive compensation in the event of a financial restatement.

Negatives

• The company had to file an amendment to its annual report, indicating a delay in providing complete information.
• The company's original filing was missing required information in Part III.

Risks

• The company's research and development activities carry inherent risks.
• The company's compensation policies could potentially encourage excessive risk-taking, although management believes this is unlikely.
• The company is subject to the risk of financial restatements due to material noncompliance with financial reporting requirements.

Management Comments

• The company's management believes that its compensation policies are not reasonably likely to have a material adverse effect on the company.
• The company's management is actively involved in monitoring research and development activities.

Industry Context

This filing is a standard annual report amendment, which is common for companies that do not file their proxy statements within the required timeframe. The information provided is typical for a publicly traded pharmaceutical company.

Comparison to Industry Standards

• The corporate governance structure, with independent directors and committees, is consistent with industry best practices for publicly traded companies.
• The executive compensation packages, including base salaries and bonuses, are within the typical range for pharmaceutical companies of similar size.
• The audit fees are comparable to those of other companies in the biotechnology sector.
• The ownership structure, with significant holdings by individuals like Phillip Frost and Fred Hassan, is not uncommon in the pharmaceutical industry.

Legal Proceedings

• On September 7, 2018, the SEC filed a complaint against Dr. Philip Frost, a director and principal stockholder, and others. On January 10, 2019, final judgments were entered against these defendants on their consent without admitting or denying the allegations.

Related Party Transactions

• On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors including Frost Gamma Investments Trust, a trust in which Phillip Frost, M.D., a director of the Company, is the trustee whereby each purchaser purchased 1,015,229 shares of common stock at a price of $1.97 per share, or two equal $2,000,000 investments. The second purchaser was Fred Hassan, who several weeks later was appointed a director of the Company.

Stakeholder Impact

• Shareholders are provided with detailed information about the company's operations, governance, and financial status.
• Employees are subject to the company's code of ethics and insider trading policy.
• The company's financial performance and governance practices impact investor confidence.

Key Dates

Keywords

annual report, amendment, corporate governance, executive compensation, directors, financial statements, audit committee, stock ownership, related party transactions, securities